July 12, 2017
Via EDGAR
Suzanne Hayes
Assistant Director
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | Reata Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-218915 |
Ladies and Gentlemen:
On behalf of Reata Pharmaceuticals, Inc. (the “Company”), and pursuant to with Rule 461 promulgated under the Securities Act of 1933, the undersigned hereby requests that the effective date of the above referenced Registration Statement on Form S-3 be accelerated to 4:00 p.m., Washington, D.C. time, on July 14, 2017, or as soon as practicable thereafter.
Thank you for your assistance in this matter.
| Very truly yours, | ||
| Reata Pharmaceuticals, Inc. | ||
| By: | /s/ Jason D. Wilson | |
| Name: | Jason D. Wilson | |
| Title: | Chief Financial Officer | |
Reata Pharmaceuticals, Inc. 2801 Gateway Drive, Suite 150 Irving, Texas 75063 www.reatapharma.com |